Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Core Insights - Marker Therapeutics reported promising results from the Phase 1 APOLLO study, showing a 66% objective response rate and 50% complete response rate in relapsed Non-Hodgkin lymphoma patients, indicating the potential of MT-601 as a treatment option for patients with limited therapy options [2][5] - The company has initiated its Off-the-Shelf program, treating the first patient in the RAPID study, which focuses on MAR-T cells for Acute Myeloid Leukemia and Myelodysplastic Syndrome [2][12] - A strategic manufacturing collaboration with Cellipont Bioservices has been established to enhance the production capabilities of MT-601, supporting clinical supply and future pivotal trials [2][12] Clinical Updates - The APOLLO study demonstrated durable responses, with five patients maintaining responses for at least six months, and three for over twelve months [5] - No dose-limiting toxicities or immune effector cell-associated neurotoxicity were observed, highlighting a favorable safety profile for MT-601 [5] - The ongoing dose expansion cohort is evaluating MT-601 at the highest dose level in patients with Diffuse Large B Cell Lymphoma who have relapsed or are ineligible for CAR-T therapy [5] Financial Highlights - As of September 30, 2025, Marker Therapeutics had cash and cash equivalents of $17.6 million and restricted cash of $1.4 million, which is expected to fund operations through the third quarter of 2026 [8] - Research and development expenses for Q3 2025 were $2.3 million, a decrease from $3.5 million in Q3 2024, while general and administrative expenses increased slightly to $1 million from $0.9 million [9] - The company reported a net loss of $2.0 million for Q3 2025, compared to a net loss of $2.3 million in the same quarter of the previous year [10] Corporate Developments - Marker Therapeutics raised approximately $10 million through its ATM facility, extending its cash runway into 2026 [2][12] - The company has received non-dilutive funding from NIH and CPRIT to support the development of MT-601 in metastatic pancreatic cancer, with a clinical program launch anticipated in the first half of 2026 [5][12] - The appointment of Kathryn Penkus Corzo to the Board of Directors was announced, effective November 1, 2025 [12]